Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

Investors

Zevra is a rare disease therapeutics company driven by science, data and patient need to create transformational therapies for diseases with limited or no treatment options.

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • SEC Filings
    • Quarterly Results
  • Contact
  • Email Alerts

With an understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed.

By letting data tell its unbiased story, our transparent narratives have overcome complex development challenges to produce needed medicines.

Nimble and determined, we push boundaries beyond what is possible to advance new therapies that meaningfully improve patients’ lives.

Stock Information

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

  • Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

    09-20-2023

  • Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

    09-09-2023

  • Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

    09-05-2023

Presentations

  • Zevra Therapeutics Corporate Presentation – September 2023

    09-13-2023

  • Zevra Corporate Update – Acer Therapeutics Acquisition

    08-31-2023

  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top